My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mind Medicine (MindMed) Inc. - Common Shares (NQ:MNMD)

10.67 +0.90 (+9.21%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mind Medicine (MindMed) Inc. - Common Shares

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
33 34 Next >
MindMed to Participate at Upcoming Investor Conferences
From Mind Medicine
Via Business Wire
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics... 
Via Benzinga
FCM Pledges to Lock Up its MindMed Shares Until June 2025 to Demonstrate its Alignment with Fellow Shareholders and Confidence in its Plan to Restore MindMed
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
MindMed And FCM Holdings' Dispute Over Clinical Path Forward Deepens
The proxy battle over MindMed’s (NASDAQ: MNMD) control has now evolved to each side requesting their position on what is best for the company's future to be validated by independent sources, vis-a-vis... 
Via Benzinga
Mind Medicine: Q1 Earnings Insights
 
Via Benzinga
Earnings Outlook For Mind Medicine
 
Via Benzinga
FCM Concerned MindMed’s Mismanagement Threatens Mental Health for Millions
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed Calls FDA Experts To Validate LSD Drug Development Strategy
In a new chapter of the management quarrel between MindMed (NASDAQ: MNMD) executives and shareholder group FCM Holdings, t 
Via Benzinga
MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed to Present Data on the Preclinical Activity of MM-402 at the American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting
From MindMed
Via Business Wire
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... 
Via Benzinga
MindMed's LSD Study For Anxiety Treatment Enrolls And Doses 100 Participants, More Expected
MindMed’s (NASDAQ: MNMD) Phase 2b clinical trial on proprietary LSD compound MM-120 targeting Generalized Anxiety Disorder (GAD) is over 50% enrolled and dosed. 
Via Benzinga
MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder (GAD)
From MindMed
Via Business Wire
FCM Holdings Accuse MindMed Braintrust Of 'Pursuing Misguided Clinical Path for MM-120'
Mind Medicine (NASDAQ: MNMD) activist shareholders FCM MM Holdings are at it again. 
Via Benzinga
FCM Director Nominees Will Put MindMed Drug Development Process Back on Track
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga
MindMed Reports Q1 2023 Financial Results, Business Highlights, Upcoming Elections
Clinical-stage biopharma company Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has reported its unaudited financial results for the quarter ended March 31, 2023, and shared the period’s business... 
Via Benzinga
FCM Releases Letter to Fellow MindMed Shareholders Highlighting Board and Management’s Track Record of Shareholder Value Destruction
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
MindMed Reports First Quarter 2023 Financial Results and Business Highlights
From MindMed
Via Business Wire
MindMed Sends Letter to Shareholders Highlighting Company’s Positive Momentum and Value-Enhancing Strategy
From MindMed
Via Business Wire
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued 
Via Benzinga
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update
From Mind Medicine (MindMed) Inc.
Via Business Wire
3 High-Growth Penny Stocks to Consider Buying in April 2023
Here are three high-growth penny stocks long-term investors may want to keep on their watch list, or buy, in April. 
Via InvestorPlace
April Psychedelic Drug Stocks Recap: The Ups And Downs
Via Talk Markets
MindMed CEO On Latest Positive Topline Phase 2 Data And Freedom Capital Management
In this new Psychedelics Exclusive podcast, TDR Founder Shadd Dales interviewed the CEO of Mind Medicine Inc. (NASDAQ: MNMD), Robert Barrow. 
Via Benzinga
MindMed to Participate in May Investor Conferences
From MindMed
Via Business Wire
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
 
Via Benzinga
FCM Nominates Exceptional Director Candidates to Restore MindMed’s Value
From Concerned Shareholders of Company MindMed
Via GlobeNewswire
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.